Loading...
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors has been heralded as a major advancement in reducing low-density lipoprotein cholesterol levels by nearly 50%. However, concerns have been raised on the added value to the health care system in terms of their costs a...
Saved in:
| Published in: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Public Library of Science
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5232345/ https://ncbi.nlm.nih.gov/pubmed/28081164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0169761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|